Paid Clinical Trials Michigan
Discover 2,123 paid clinical trials in Michigan. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
MyeloMATCHComparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT06672146
Conditions
Acute Myeloid Leukemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Marrow Aspiration
Bone Marrow Biopsy
Decitabine and Cedazuridine
Enasidenib
Observational StudyStent Omission After Ureteroscopy and Lithotripsy in the Michigan Urological Surgery Improvement Collaborative
Sponsor:
University of Michigan
Location:
Code:
NCT05866081
Conditions
Stone, Kidney
Stone Ureter
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Standard of care stent placement
No stent placement
Surveys
Remibrutinib vs. TeriflunomideEfficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT05156281
Conditions
Relapsing Multiple Sclerosis
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Not accepted
Interventions
Remibrutinib
Teriflunomide
DAY301To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor:
Day One Biopharmaceuticals, Inc.
Location:
Code:
NCT06752681
Conditions
Advanced or Metastatic Solid Tumors
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
DAY301
Gene TherapyGene Therapy for ACM Due to a PKP2 Pathogenic Variant
Sponsor:
Lexeo Therapeutics
Location:
Code:
NCT06109181
Conditions
Arrhythmogenic Cardiomyopathy
PKP2-ACM
PKP2-ARVC
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
LX2020
P-CD19CD20-ALLO1P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Sponsor:
Poseida Therapeutics, Inc.
Location:
Code:
NCT06014762
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High-grade B-cell Lymphoma
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Transformed Follicular Lymphoma (tFL)
Follicular Lymphoma Grade 3B
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
P-CD19CD20-ALLO1
Rimiducid
PF-08046054A Study of SGN-PDL1V in Advanced Solid Tumors
Sponsor:
Seagen Inc.
Location:
Code:
NCT05208762
Conditions
Carcinoma, Non-Small-Cell Lung
Squamous Cell Carcinoma of the Head and Neck
Esophageal Squamous Cell Carcinoma
Ovarian Neoplasms
Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
PF-08046054
pembrolizumab
GLIADEL vs. Stereotactic RadiosurgeryA Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease
Sponsor:
University of Nebraska
Location:
Code:
NCT04222062
Conditions
Brain Tumor - Metastatic
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Carmustine 7.7Mg Wafer
Crenolanib vs. MidostaurinStudy of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Sponsor:
Arog Pharmaceuticals, Inc.
Location:
Code:
NCT03258931
Conditions
Newly Diagnosed FLT3 Mutated AML
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Crenolanib
Midostaurin
Cytarabine
Duanorubicin
BomedemstatA Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT06351631
Conditions
Thrombocythemia, Essential
Primary Myelofibrosis
Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bomedemstat